$1.93 EPS Expected for Eli Lilly and Company (NYSE:LLY) This Quarter

Analysts predict that Eli Lilly and Company (NYSE:LLYGet Rating) will post earnings of $1.93 per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Eli Lilly and’s earnings, with estimates ranging from $1.81 to $2.12. Eli Lilly and posted earnings of $1.87 per share during the same quarter last year, which would suggest a positive year over year growth rate of 3.2%. The firm is expected to report its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Eli Lilly and will report full-year earnings of $8.34 per share for the current financial year, with EPS estimates ranging from $8.15 to $8.80. For the next financial year, analysts forecast that the company will report earnings of $9.56 per share, with EPS estimates ranging from $9.00 to $9.86. Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that follow Eli Lilly and.

Eli Lilly and (NYSE:LLYGet Rating) last issued its quarterly earnings data on Thursday, April 28th. The company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.30. Eli Lilly and had a net margin of 20.90% and a return on equity of 97.58%. The business had revenue of $7.81 billion for the quarter, compared to analysts’ expectations of $7.29 billion. During the same period in the previous year, the business earned $1.87 earnings per share. The company’s revenue was up 14.8% on a year-over-year basis.

Several brokerages have commented on LLY. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and from $234.00 to $264.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Morgan Stanley boosted their price target on shares of Eli Lilly and from $364.00 to $369.00 in a research report on Friday, April 29th. Daiwa Capital Markets assumed coverage on shares of Eli Lilly and in a research report on Thursday, March 10th. They issued an “outperform” rating and a $286.00 price target on the stock. StockNews.com downgraded Eli Lilly and from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 30th. Finally, DZ Bank upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $291.00 price objective on the stock in a report on Friday, January 21st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $302.56.

In other Eli Lilly and news, SVP Ilya Yuffa sold 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 15th. The stock was sold at an average price of $237.45, for a total transaction of $237,450.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Donald A. Zakrowski sold 1,660 shares of the company’s stock in a transaction that occurred on Friday, February 25th. The stock was sold at an average price of $243.84, for a total value of $404,774.40. The disclosure for this sale can be found here. In the last three months, insiders sold 1,088,551 shares of company stock valued at $307,943,730. 0.12% of the stock is currently owned by company insiders.

A number of institutional investors have recently made changes to their positions in LLY. Morgan Stanley boosted its position in Eli Lilly and by 8.2% during the second quarter. Morgan Stanley now owns 3,822,819 shares of the company’s stock worth $877,414,000 after purchasing an additional 289,490 shares during the period. Continuum Advisory LLC lifted its holdings in shares of Eli Lilly and by 6.1% during the third quarter. Continuum Advisory LLC now owns 1,100 shares of the company’s stock worth $254,000 after buying an additional 63 shares during the last quarter. MEMBERS Trust Co lifted its holdings in shares of Eli Lilly and by 106.6% during the third quarter. MEMBERS Trust Co now owns 2,392 shares of the company’s stock worth $552,000 after buying an additional 1,234 shares during the last quarter. Checchi Capital Advisers LLC lifted its holdings in shares of Eli Lilly and by 1.8% during the third quarter. Checchi Capital Advisers LLC now owns 9,664 shares of the company’s stock worth $2,233,000 after buying an additional 167 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its holdings in shares of Eli Lilly and by 12.9% during the third quarter. Candriam Luxembourg S.C.A. now owns 137,547 shares of the company’s stock worth $31,779,000 after buying an additional 15,756 shares during the last quarter. 82.75% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and stock traded up $0.81 during midday trading on Friday, hitting $291.63. The company’s stock had a trading volume of 2,337,673 shares, compared to its average volume of 2,662,391. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 1.60. The stock’s 50-day moving average price is $289.22 and its 200-day moving average price is $266.49. Eli Lilly and has a 12 month low of $193.11 and a 12 month high of $314.00. The company has a market capitalization of $277.10 billion, a PE ratio of 43.20, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 10th. Investors of record on Monday, May 16th will be paid a $0.98 dividend. The ex-dividend date of this dividend is Friday, May 13th. This represents a $3.92 annualized dividend and a dividend yield of 1.34%. Eli Lilly and’s payout ratio is 58.07%.

Eli Lilly and Company Profile (Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Read More

Get a free copy of the Zacks research report on Eli Lilly and (LLY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.